Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses
第一作者机构：[1]Beijing Tongren Hosp, Beijing, Peoples R China[2]Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Shurong,Zhang Boyao,Li Xinyu,et al.Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Zhang, Shurong,Zhang, Boyao,Li, Xinyu,Dang, Shoutao&Zhao, Jingyang.(2023).Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Zhang, Shurong,et al."Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学